The Department of Veterans Affairs (VA) National Acquisition Center (NAC) is seeking proposals for Mesalamine 1200mg tablets to supply both the VA and the Department of Defense (DoD). Managed by the NAC Pharmaceuticals office, this procurement uses the Pharmaceutical Prime Vendor (PPV) program for distribution. The contract includes a base year and four one-year option periods, totaling five years of performance. A recent amendment, 0001, extended the proposal submission deadline. The requirement falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and PSC code 6505 (Drugs and Biologicals). Proposals must meet technical and regulatory standards, including the Drug Supply Chain Security Act (DSCSA) and unique National Drug Code (NDC) registration. The solicitation package includes the base SF-1449 and Amendment 0001, which detail the scope, packaging specifications, and pricing instructions. Proposals are due by June 18, 2026, at 2:30 PM CDT. The procurement is governed by the original SF-1449 solicitation and Amendment 0001. These documents define the technical specifications, pricing, and regulatory mandates for pharmaceutical distribution. The VA National Acquisition Center is procuring Mesalamine 1200mg Enteric Coated (EC) Delayed Release (DR) tablets for the VA and DoD via the Pharmaceutical Prime Vendor (PPV) program.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.
Contact and place of performance
Youlanda Duggar
Not specified
Extend due date of offers